News

Ideas That Generate Results

With the availability of the well-qualified and highly competent medical staff at lower costs and the government initiatives to encourage investments in the clinical trials market, the Russian Clinical Trials Market is forecasted to grow at a CAGR of around 8.5% during 2009-2012, says our new research report "Clinical Trials Market in Russia".

According to our report, foreign pharmaceutical players are showing keen interest in conducting clinical trials in Russia. Apart from that, the government's well-laid collaboration projects with other healthcare players such as health-insurers and drug makers encouraged the Russian pharmaceutical giants to participate in the clinical trials market, raising their market share from 28% in 2007 to 33% in 2008.

The strength of the industry can also be realized from the fact that most of the trials being conducted in Russia are in advanced phases, showing the higher probability of the successful launch of the drug in this market.

The market is expected to retain its attractiveness as the country enjoys key advantages over other well-developed clinical trials markets like that in the US and Europe. The country has a large patient pool concentrated in few urban areas that allows easy accessibility for the patient enrolment in a clinical study. Besides, well-qualified medical staff, smooth and effective regulatory framework, and ICH GCP compliant sites ensure the generation of best results in a clinical trial study. 

"Clinical Trials Market in Russia" gives the extensive overview about the clinical trials market in Russia. The report thoroughly studies the impact of various factors affecting the industry's performance. It also examines the present and past market performance to arrive at reasonable forecasts. Besides, the report will help to identify the key areas of performance across different market segments. The report also highlights the key challenges involved in conducting clinical research study in Russia.

Besides, the report points out the emerging therapy areas, the growth in the number of global clinical trials, the regulatory stipulations that are vital to follow in order to conduct the clinical research smoothly in Russia.

For more information visit: http://www.rncos.com/Report/IM189.htm